SCHEMBL2094545

SCHEMBL2094545

O=C(O)N(c1ccccc1)c1cccc(C(F)(F)F)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.49
KMT2A Q03164 5/20 0.49
MAPT P10636 3/20 0.49
HTT P42858 2/20 0.49
RAB9A P51151 1/20 0.49
CES2 O00748 1/20 0.49
PTGIR P43119 1/20 0.48
LMNA P02545 1/20 0.46
SRD5A2 P31213 1/20 0.45
KAT6A Q92794 1/20 0.44
MAOB P27338 1/20 0.44
KCNK3 O14649 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
ALDH1A1 P00352 1/20 0.43
TSHR P16473 1/20 0.43
TACR1 P25103 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TP53 P04637 1/20 0.43
ACP3 P15309 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2094544 0.88 MEN1 (0.47) MEN1KMT2AMAPTHTTRAB9A
SCHEMBL29116640 0.88 TACR1 (0.51) CES2NPSR1TACR1
SCHEMBL1118844 0.87 PTGIR (0.46) MEN1KMT2AMAPTHTTRAB9A
SCHEMBL28217598 0.87 PTGIR (0.46) MEN1KMT2AMAPTHTTRAB9A
SCHEMBL2097683 0.84 NPSR1 (0.48) KMT2AMAPTHTTRAB9ACES2
SCHEMBL6245400 0.83 PTGIR (0.52) MEN1KMT2AMAPTHTTRAB9A
SCHEMBL14300675 0.82 TACR1 (0.43) MEN1KMT2AMAPTHTTRAB9A
SCHEMBL10670225 0.82 NPSR1 (0.49) MEN1KMT2AMAPTHTTRAB9A
SCHEMBL4682247 0.81 MTOR (0.48) PTGIRMAOB
SCHEMBL4283231 0.81 TAS2R14 (0.46) MEN1KMT2APTGIRLMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 MEN1 4525/4885KMT2A 3324/4885MAPT 4299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.